Show simple item record

dc.contributor.authorBurger, E A
dc.contributor.authorOrtendahl, J
dc.contributor.authorSy, Stephen
dc.contributor.authorKristiansen, I S
dc.contributor.authorKim, Jane Jooyun
dc.date.accessioned2013-12-11T15:27:37Z
dc.date.issued2012
dc.identifier.citationBurger, E A, J D Ortendahl, S Sy, I S Kristiansen, and J J Kim. 2012. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in norway. British Journal of Cancer 106(9): 1571-1578.en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11365847
dc.description.abstractBackground: New screening technologies and vaccination against human papillomavirus (HPV), the necessary cause of cervical cancer, may impact optimal approaches to prevent cervical cancer. We evaluated the cost-effectiveness of alternative screening strategies to inform cervical cancer prevention guidelines in Norway. Methods: We leveraged the primary epidemiologic and economic data from Norway to contextualise a simulation model of HPV-induced cervical cancer. The current cytology-only screening was compared with strategies involving cytology at younger ages and primary HPV-based screening at older ages (31/34+ years), an option being actively deliberated by the Norwegian government. We varied the switch-age, screening interval, and triage strategies for women with HPV-positive results. Uncertainty was evaluated in sensitivity analysis. Results: Current cytology-only screening was less effective and more costly than strategies that involve switching to primary HPV testing in older ages. For unvaccinated women, switching at age 34 years to primary HPV testing every 4 years was optimal given the Norwegian cost-effectiveness threshold ($83 000 per year of life saved). For vaccinated women, a 6-year screening interval was cost-effective. When we considered a wider range of strategies, we found that an earlier switch to HPV testing (at age 31 years) may be preferred. Conclusions: Strategies involving a switch to HPV testing for primary screening in older women is expected to be cost-effective compared with current recommendations in Norway.en_US
dc.language.isoen_USen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofdoi:10.1038/bjc.2012.94en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341862/pdf/en_US
dash.licenseLAA
dc.subjectcost-effectivenessen_US
dc.subjectcervical cancer screeningen_US
dc.subjectHPV vaccinationen_US
dc.titleCost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norwayen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBritish Journal of Canceren_US
dash.depositing.authorKim, Jane Jooyun
dc.date.available2013-12-11T15:27:37Z
dc.identifier.doi10.1038/bjc.2012.94*
dash.contributor.affiliatedSy, Stephen
dash.contributor.affiliatedOrtendahl, Jesse
dash.contributor.affiliatedKim, Jane


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record